Changing Paradigms of Non-small Cell Lung Cancer Treatment

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2019 Jan 12

PMID 30631585

Citations 1

Authors

Francesco Guerrera

Fabrizio Tabbo

Enrico Ruffini

Pietro Bertoglio

Affiliations

Soon will be listed here.

Citing Articles

Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers.

Mielgo-Rubio X, Calvo V, Luna J, Remon J, Martin M, Berraondo P Cancers (Basel). 2020; 12(11).

PMID: 33233705 PMC: 7699975. DOI: 10.3390/cancers12113459.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

William Jr W, Pataer A, Kalhor N, Correa A, Rice D, Wistuba I . Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013; 8(2):222-8. PMC: 3549050. DOI: 10.1097/JTO.0b013e3182774108. View

Ledford H . Cancer treatment: The killer within. Nature. 2014; 508(7494):24-6. DOI: 10.1038/508024a. View

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

Sun W, Li G, Wan J, Zhu J, Shen W, Zhang Z . Circulating tumor cells: A promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy. Oncotarget. 2016; 7(43):69507-69517. PMC: 5342494. DOI: 10.18632/oncotarget.10875. View

Liu J, Blake S, Yong M, Harjunpaa H, Ngiow S, Takeda K . Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016; 6(12):1382-1399. DOI: 10.1158/2159-8290.CD-16-0577. View

Coroller T, Agrawal V, Huynh E, Narayan V, Lee S, Mak R . Radiomic-Based Pathological Response Prediction from Primary Tumors and Lymph Nodes in NSCLC. J Thorac Oncol. 2016; 12(3):467-476. PMC: 5318226. DOI: 10.1016/j.jtho.2016.11.2226. View

Guerrera F, Renaud S, Tabbo F, Filosso P . How to design a randomized clinical trial: tips and tricks for conduct a successful study in thoracic disease domain. J Thorac Dis. 2017; 9(8):2692-2696. PMC: 5594116. DOI: 10.21037/jtd.2017.06.147. View

Dieleman J, Peelen L, Coulson T, Tran L, Reid C, Smith J . Age and other perioperative risk factors for postoperative systemic inflammatory response syndrome after cardiac surgery. Br J Anaesth. 2017; 119(4):637-644. DOI: 10.1093/bja/aex239. View

10.

Bertoglio P, Renaud S, Guerrera F . Unless I see, I will not believe. J Thorac Dis. 2017; 9(9):2835-2838. PMC: 5708374. DOI: 10.21037/jtd.2017.08.111. View

11.

Filosso P, Guerrera F, Lausi P, Ruffini E . Locally advanced non-small cell lung cancer treatment: another step forward. J Thorac Dis. 2018; 9(12):4908-4911. PMC: 5757015. DOI: 10.21037/jtd.2017.11.103. View

12.

Bott M, Cools-Lartigue J, Tan K, Dycoco J, Bains M, Downey R . Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors. Ann Thorac Surg. 2018; 106(1):178-183. PMC: 6357770. DOI: 10.1016/j.athoracsur.2018.02.030. View

13.

Yeh J, Marrone K, Forde P . Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer. J Thorac Dis. 2018; 10(Suppl 3):S451-S459. PMC: 5861269. DOI: 10.21037/jtd.2018.01.109. View

14.

Okamura A, Watanabe M, Fukudome I, Yamashita K, Yuda M, Hayami M . Relationship Between Visceral Obesity and Postoperative Inflammatory Response Following Minimally Invasive Esophagectomy. World J Surg. 2018; 42(11):3651-3657. DOI: 10.1007/s00268-018-4675-x. View

15.

Raju S, Joseph R, Sehgal S . Review of checkpoint immunotherapy for the management of non-small cell lung cancer. Immunotargets Ther. 2018; 7:63-75. PMC: 6074780. DOI: 10.2147/ITT.S125070. View

16.

Forde P, Chaft J, Pardoll D . Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018; 379(9):e14. DOI: 10.1056/NEJMc1808251. View

17.

Ghysen K, Vansteenkiste J . Immunotherapy in patients with early stage resectable nonsmall cell lung cancer. Curr Opin Oncol. 2018; 31(1):13-17. DOI: 10.1097/CCO.0000000000000497. View